111
Participants
Start Date
February 28, 2014
Primary Completion Date
February 29, 2020
Study Completion Date
February 29, 2020
Capecitabine/cisplatin
Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
S-1/cisplatin
S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
Capecitabine/oxaliplatin
Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
5-fluorouracil/oxaliplatin
5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
Capecitabine
Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)
S-1
S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 30mg/m2 po bid)
5-fluorouracil
5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
Hallym University Sacred Heart Hospital, Anyang
Inje University Haeundae Paik Hospital, Busan
Yeongnam University Medical Center, Daegu
Inje University Sanggye Paik Hospital, Seoul
Kangbuk Samsung Hospital, Seoul
The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu-si
Chungbuk National University Hospital, Cheongju-si
Kyungpook National University Medical Center, Daegu
National Cancer Center, Goyang
Gachon University Gil Medical Center, Incheon
Inje University Pusan Paik Hospital, Pusan
Seoul National University Bundang Hospital, Seongnam
Asan Medical Center, Seoul
SMG-SNU Boramae Medical Center, Seoul
Ministry of Health & Welfare, Korea
OTHER_GOV
Korean Cancer Study Group
OTHER
Seoul National University Hospital
OTHER